Showing 4,441 - 4,460 results of 7,608 for search '"oncology"', query time: 0.11s Refine Results
  1. 4441
  2. 4442
  3. 4443
  4. 4444
  5. 4445
  6. 4446
  7. 4447
  8. 4448
  9. 4449

    Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club by Katarzyna Winter, Renata Talar-Wojnarowska, Andrzej Dąbrowski, Małgorzata Degowska, Marek Durlik, Anita Gąsiorowska, Stanisław Głuszek, Grażyna Jurkowska, Aleksandra Kaczka, Paweł Lampe, Tomasz Marek, Anna Nasierowska-Guttmejer, Ewa Nowakowska-Duława, Grażyna Rydzewska, Janusz Strzelczyk, Zbigniew Śledziński, Ewa Małecka-Panas

    Published 2019-03-01
    “…A vast majority of the statements are based on data obtained in clinical studies and experts’ recommendations on PDAC management, including the following guidelines: International Association of Pancreatology/European Pancreatic Club (IAP/EPC), American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), National Comprehensive Cancer Network (NCCN) and Polish Society of Gastroenterology (PSG) and The National Institute for Health and Care Excellence (NICE). …”
    Get full text
    Article
  10. 4450
  11. 4451
  12. 4452
  13. 4453

    Atezolizumab neutralizing assay development: a novel way of evaluating assay cutpoint after sample pretreatment by Rachel Melendez, Jane Ruppel, Cecilia Leddy, Jenny Yang, Ann Brady, Yenny Webb-Vargas, Jochen Brumm, Lynn Kamen, Yuan Song

    Published 2025-02-01
    “…Abstract Atezolizumab, a biotherapeutic monoclonal antibody directed against PD-L1, has been shown to be efficacious in multiple oncology indications. In clinical trials, a subset of patients developed anti-atezolizumab antibodies, necessitating the development of a neutralizing antibody (NAb) assay. …”
    Get full text
    Article
  14. 4454
  15. 4455
  16. 4456
  17. 4457
  18. 4458
  19. 4459

    A pivotal decade for bispecific antibodies? by Marlena Surowka, Christian Klein

    Published 2024-12-01
    “…In the 2020s, the approval of additional bsAbs can be expected in hematological malignancies, solid tumors and non-oncology indications, establishing bsAbs as essential part of the therapeutic armamentarium.…”
    Get full text
    Article
  20. 4460